ConcertAI, Astellas partner on RWE in acute myeloid leukemia

The partnership will focus on using real-world evidence to improve understanding of responses among patients with acute myeloid leukemia whose disease carries mutations in the FLT3 gene. Astellas markets a drug for FLT3-positive AML, Xospata, approved in November 2018.

Read More